July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
The role of SRGAP2 in glaucomatous optic neuropathy
Author Affiliations & Notes
  • Zai-Long Chi
    Laboratory of Neurovascular Biology, The Eye Hospital of Wenzhou Medical University, Wenzhou, China
  • Footnotes
    Commercial Relationships   Zai-Long Chi, None
  • Footnotes
    Support   National Natural Science Foundation of China (Grant No. 81770918)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3736. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Zai-Long Chi; The role of SRGAP2 in glaucomatous optic neuropathy
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):3736.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Glaucoma is the leading cause of irreversible blindness worldwide which characterized by progressive retinal ganglion cell (RGC) degeneration and vision loss. The pathogenesis of glaucoma is poorly understood. SLIT-ROBO Rho GTPase-activating protein 2 (SRGAP2) plays a pivotal role in the central nervous system while its function in the retina is unclear. In order to explore the biological basis of SRGAP2, we combined gene knock out (KO) mice and optic nerve crush (ONC) models to investigate its function on RGC survival.

Methods : All animal experiments were conducted in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. We generated SRGAP2 KO mice using CRISPER/CAS9 technology with the C57BL/6J background. Immunohistochemical and optical coherence tomography (OCT) analysis were performed for phenotype study after ONC. Electroretinogram (ERG) analysis was performed for assessment of retinal function. Stable SRGAP2 knockdown cell line was generated using lentivirus-mediated RNA interference. Western blotting analysis was performed against PI3K-AKT-mTOR and JAK-STAT3 signaling pathway. Two-tailed Student's t-test was used for statistical analysis.

Results : SRGAP2 was expressed broadly in the neural retina, whereas especially higher in RGCs. Expression of SRGAP2 were increased significantly in the retina of C57BL/6J mice. SRGAP2 KO mice (n=4) observed prevention of RGC loss compared to wild type controls (n=6) 7 days after ONC (p=0.023). OCT analysis showed the thicker retina in KO mice (n=8) especially in the RGC and IPL layers as compared to wild type (n=12) after surgery (p=0.01). In addition, ERG analysis demonstrated that the retinal function was restored dramatically in KO mice one week after ONC (n=7 each group, p=0.002). Stable SRGAP2 knockdown cell line studies have revealed increased phosphorylation of AKT, mTOR, S6 and STAT3.

Conclusions : SRGAP2 may play an important role in the retinal development and neurodegeneration through regulating PI3K-AKT-mTOR and JAK-STAT3 signaling pathway.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.